International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2006
Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
We evaluated whether posttreatment prostatic-specific antigen doubling time (PSADT) was predictive of prostate cancer mortality by testing the Prentice requirements for a surrogate endpoint. ⋯ Prostatic specific antigen doubling time is significantly associated with CSS, but did not meet all of Prentice's requirements for a surrogate endpoint of CSS. Thus, the risk of dying of prostate cancer is not fully explained by PSADT.
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2006
Controlled Clinical TrialA comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma.
The aim of this study was to compare toxicity/efficacy of conventional radiotherapy using delayed accelerated concomitant boost radiotherapy (CBRT) vs. intensity-modulated radiotherapy (IMRT) in the setting of concurrent chemotherapy (CT) for locally advanced oropharyngeal carcinoma. ⋯ In the setting of CT for locally advanced oropharyngeal carcinoma, IMRT results in lower toxicity and similar treatment outcomes when compared with CBRT.
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2006
Comparative Study Controlled Clinical TrialIntensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy.
Xerostomia is a severe complication after radiotherapy for oropharyngeal cancer, as the salivary glands are in close proximity with the primary tumor. Intensity-modulated radiotherapy (IMRT) offers theoretical advantages for normal tissue sparing. A Phase II study was conducted to determine the value of IMRT for salivary output preservation compared with conventional radiotherapy (CRT). ⋯ IMRT significantly reduces the number of parotid flow complications for patients with oropharyngeal cancer.
-
Int. J. Radiat. Oncol. Biol. Phys. · Nov 2006
Comment LetterAdjuvant malignant mesothelioma radiotherapy: How many difficulties! In regard to: Allen et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma (Int J Radiat Oncol Biol Phys 2006;65:640-645) and Gupta et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma (Int J Radiat Oncol Biol Phys 2005;63:1045-1052).